3-hydroxybutyrate

Overview

3-hydroxybutyrate, also known as β-hydroxybutyrate (BHB), is a ketone body produced primarily in the liver during states of increased fatty acid oxidation, such as fasting or carbohydrate restriction. It serves as an alternative energy substrate for extrahepatic tissues, including the brain, and is increasingly recognized as a signaling metabolite rather than only a fuel source.

In biomedical research, 3-hydroxybutyrate is studied for its associations with energy metabolism, neuroprotection, inflammation, oxidative stress, and cell survival pathways. Recent work has linked elevated BHB to modulation of PI3K/AKT/GSK-3β signaling, antioxidant and anti-apoptotic effects, and changes in gut-derived Metabolites such as butyrate and lipoxin A4. These findings place 3-hydroxybutyrate at the intersection of metabolic adaptation and disease-modifying biology in conditions including Cognitive decline, hypoxic-ischemic injury, renal dysfunction, and osteoporosis-related gut microbiota changes.

Focus of Latest Publications

Recent publications have examined 3-hydroxybutyrate mainly as a metabolic mediator associated with protective effects in neurological and systemic disease models.

In a study of intermittent fasting in D-galactose-induced aging rats, increased β-hydroxybutyrate was associated with attenuation of Cognitive decline. The authors reported that the benefit of intermittent fasting was at least partly linked to BHB elevation and modulation of PI3K/AKT/GSK-3β signaling. This places 3-hydroxybutyrate in a mechanistic framework relevant to aging-associated brain dysfunction and pathways implicated in neuronal survival and synaptic integrity.

Another study investigated β-hydroxybutyrate in hypoxic-ischemic encephalopathy mice and found that it alleviated motor impairment and neurological damage. The publication described BHB as an abundant ketone body synthesized in the liver with energy-supplying, anti-inflammatory, antioxidant, and anti-apoptotic activities. In this context, 3-hydroxybutyrate was studied as a neuroprotective factor in a severe injury model involving hypoxia and ischemia, with outcomes assessed through behavioral and histological measures.

A separate pharmacology study on tramadol-driven renal dysfunction reported that treatment disrupted ketogenic metabolism, reducing concentrations of β-hydroxybutyrate, NAD+, and acetyl-CoA, and inhibiting HMGCS2 expression. Although 3-hydroxybutyrate was not the intervention, it was a key readout of impaired ketogenesis. The findings support its use as a metabolic marker reflecting altered energy handling and mitochondrial substrate availability in drug-induced renal injury. chrysin was reported to attenuate these effects, suggesting restoration of ketogenic metabolism as part of its protective action.

In a gut microbiota-focused osteoporosis study, a composite protein enriched with threonine, lysine, and tryptophan promoted production of several key Metabolites, including β-hydroxybutyrate, lipoxin A4, indole-3-propionic acid, and butyrate. Here, 3-hydroxybutyrate appeared as part of a broader metabolite profile associated with beneficial host-microbiota interactions. The inclusion of tryptophan-related metabolism and other bioactive Metabolites suggests that BHB may participate in systemic metabolic remodeling linked to bone health.

Across these studies, 3-hydroxybutyrate was consistently associated with adaptive metabolism and tissue protection. It was linked to Cognitive decline, brain injury, renal dysfunction, and osteoporosis-related metabolic changes, often in conjunction with related entities such as brain atrophy, Interleukin 4, superoxide dismutase, and tryptophan. The overall literature presented here supports BHB as both a biomarker of ketogenesis and a biologically active mediator with potential relevance to neurodegeneration and inflammatory regulation.

Key Publications

May Intermittent Fasting Attenuates Cognitive Decline in D-Galactose-Induced Aging Rats in Association with β-Hydroxybutyrate and PI3K/AKT/GSK-3β Signaling. (Neurochemical research, 2026, PMID 42207407): "...at least partly in association with BHB elevation and modulation of PI3K/AKT/GSK-3β signaling."
May β-hydroxybutyrate alleviates motor impairment and neurological damage in hypoxic-ischemic encephalopathy mice. (Behavioural brain research, 2026, PMID 41786046): "β-hydroxybutyrate (BHB) is an abundant ketone body synthesized in the liver, possesses energy supply, anti-inflammatory, antioxidant, and anti-apoptotic activities."
May Chrysin attenuates tramadol-driven renal dysfunction via regulation of RNA networks, antioxidant pathways, and ketogenic metabolism. (European journal of pharmacology, 2026, PMID 42002091): "TR interrupted LINC01187 and additional regulatory RNA networks, reduced the concentrations of β-hydroxybutyrate, NAD+, and acetyl-CoA, essential for ketogenesis, and inhibited HMGCS2 expression."
Apr A composite protein enriched with threonine, lysine, and tryptophan improves osteoporosis by modulating the composition and metabolism of the gut microbiota. (Food & function, 2026, PMID 41915427): "and promoted the production of key metabolites such as β-hydroxybutyrate (β-HB), lipoxin A4 (LXA4), indole-3-propionic acid (IPA), and butyrate."